EcoDrugPlus

Mitogen-Activated Protein Kinase 10

Ensembl ID : ENSEBUG00000007037
Gene Symbol: MAPK10
1 Cross references
225 Possible Orthologues:

Mitogen-Activated Protein Kinase 14a

Ensembl ID : ENSEBUG00000010280
Gene Symbol: MAPK14A
1 Cross references
297 Possible Orthologues:

Mitogen-Activated Protein Kinase 8a

Ensembl ID : ENSEBUG00000005389
Gene Symbol: MAPK8A
1 Cross references
295 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase 1

Ensembl ID : ENSEBUG00000007971
Gene Symbol: MAP2K1
1 Cross references
484 Possible Orthologues:

Mitogen-Activated Protein Kinase Kinase Kinase 13

Ensembl ID : ENSEBUG00000006010
Gene Symbol: MAP3K13
1 Cross references
198 Possible Orthologues:

Monoamine Oxidase A

Ensembl ID : ENSEBUG00000006542
Gene Symbol: MAOA
1 Cross references
148 Possible Orthologues:

Natriuretic Peptide Receptor 1

Ensembl ID : ENSEBUG00000016846
Gene Symbol: NPR1
1 Cross references
185 Possible Orthologues:

Natriuretic Peptide Receptor 3

Ensembl ID : ENSEBUG00000003361
Gene Symbol: NPR3
1 Cross references
211 Possible Orthologues:

Neuropeptide Y Receptor Y2, Like

Ensembl ID : ENSEBUG00000006764
Gene Symbol: NPY2RL
1 Cross references
349 Possible Orthologues:

Nicotinamide Phosphoribosyltransferase

Ensembl ID : ENSEBUG00000004908
Gene Symbol: NAMPT
1 Cross references
235 Possible Orthologues:

Notch Receptor 1b

Ensembl ID : ENSEBUG00000011495
Gene Symbol: NOTCH1B
1 Cross references
267 Possible Orthologues:

Nuclear Receptor Subfamily 1 Group H Member 2

Ensembl ID : ENSEBUG00000016740
Gene Symbol: NR1H2
1 Cross references
289 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects from the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).